Research Use Only. Scientific reference for laboratory professionals. Not for human consumption or clinical use. RUO policy

Compound research overview

Ipamorelin

Ipamorelin - literature-framed laboratory reference

Introduction

Ipamorelin is a selective growth hormone secretagogue (ghrelin receptor agonist) characterized in classical pharmacological literature. It is supplied here strictly for laboratory research use only.

Chemical and structural summary

Pentapeptide GHS (Aib-His-D-2-Nal-D-Phe-Lys-NH2). CAS 170851-70-4. Lyophilized research material; confirm CoA.

Catalog nameIpamorelin
CategoryGH Axis Research
CAS170851-70-4
Molecular weight noteAbout 711.9 g/mol (reference)
DocumentationLot-specific CoA available on request

View product specifications and ordering

Research history and background

Ipamorelin was described as a selective GH secretagogue with relatively low effects on ACTH/cortisol in comparative animal pharmacology relative to some other GHRPs, making it a useful research tool for GH axis studies.

Areas investigated in laboratory and preclinical research

The following themes appear in peer-reviewed literature. Inclusion here means the topic has been studied or reviewed scientifically - not that catalog materials are validated for any endpoint.

  • GHS-R1a (ghrelin receptor) pharmacology
  • Pituitary GH release models in laboratory animals
  • Selectivity profiling versus other growth hormone-releasing peptides

Mechanisms discussed in the literature

Ipamorelin acts as an agonist at the growth hormone secretagogue receptor (ghrelin receptor), stimulating GH release via pathways distinct from GHRH receptor activation. Descriptions reflect research pharmacology, not clinical use guidance for RUO products.

Key published studies and reviews

Prefer primary literature. Open links in a new tab. Always read full papers for methods and limitations.

  1. Raun K, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. PubMed 9849822.

Known limitations and evidence gaps

Older pharmacological papers do not establish modern clinical approval for research reagents. Combination marketing claims with other GH-axis peptides are not literature conclusions for RUO supply.

Laboratory handling notes

General laboratory practice for lyophilized peptides includes cool, dry storage protected from moisture and light, careful reconstitution with appropriate research diluents, and documentation of lot numbers. See educational guides for process literacy - not product-specific validated stability claims.

Regulatory status note

Materials sold by VialVibes are Research Use Only. They are not intended for human consumption, clinical administration, or veterinary use, and are not sold as FDA-approved drugs. Where the scientific literature discusses approved medicines or investigational drug programs involving the same active structure class, those regulated products remain distinct from RUO research reagents. See Research Use Only - what it means and the legal RUO policy.

Scientific reference only - Research Use Only. Content prepared for laboratory professionals. Citations describe published research and do not constitute product claims, medical advice, or authorization for human use of research materials. VialVibes is operated by APEX Research, LLC.

Related research pages